Lilly begins world's first study of a potential COVID-19 antibody treatment in humans
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19.
This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19.
GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
- Details
- Category: GlaxoSmithKline
GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant system.
Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
- Details
- Category: Novartis
Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today.
The research - which covered 2,502 tech professionals in the US, UK, Germany, China and India, conducted between May and June 2020 - targeted respondents from a variety of sectors and organizations with the objective to study perception shifts of the industry in the wake of the global COVID-19 pandemic.
Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases.
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
- Details
- Category: Novartis
Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible. The recruitment challenge facing our HCQ trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19.
Bayer supports "The Challenge Initiative" of Johns Hopkins Bloomberg School of Public Health with 10 million USD
- Details
- Category: Bayer
Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public Health, the initiative provides women and girls living in urban poverty in cities in Africa and Asia with family planning and reproductive health solutions.
Sanofi invests to make France its world class center of excellence in vaccine research and production
- Details
- Category: Sanofi
Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks. Aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines.
More Pharma News ...
- AstraZeneca to supply Europe with up to 400 million doses of Oxford University's vaccine at no profit
- Gilead announces results from Phase 3 Trial of remdesivir in patients with moderate COVID-19
- Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July
- New consortium EUbOPEN will provide tools to unlock disease biology
- AstraZeneca takes next steps towards broad and equitable access to Oxford University's COVID-19 vaccine
- Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients
- Bayer to support Harvard Research Study to evaluate trust in science, including in COVID-19 pandemic